company background image
FBRX logo

Forte Biosciences NasdaqCM:FBRX Stock Report

Last Price

US$0.71

Market Cap

US$25.8m

7D

7.5%

1Y

-28.0%

Updated

26 Mar, 2024

Data

Company Financials +

Forte Biosciences, Inc.

NasdaqCM:FBRX Stock Report

Market Cap: US$25.8m

FBRX Stock Overview

Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States.

FBRX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Forte Biosciences, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Forte Biosciences
Historical stock prices
Current Share PriceUS$0.71
52 Week HighUS$1.29
52 Week LowUS$0.38
Beta1.65
1 Month Change2.86%
3 Month Change-2.91%
1 Year Change-27.99%
3 Year Change-97.79%
5 Year Changen/a
Change since IPO-95.78%

Recent News & Updates

Is Forte Biosciences (NASDAQ:FBRX) In A Good Position To Deliver On Growth Plans?

Mar 14
Is Forte Biosciences (NASDAQ:FBRX) In A Good Position To Deliver On Growth Plans?

Recent updates

Is Forte Biosciences (NASDAQ:FBRX) In A Good Position To Deliver On Growth Plans?

Mar 14
Is Forte Biosciences (NASDAQ:FBRX) In A Good Position To Deliver On Growth Plans?

Large Forte Biosciences shareholder scolds company board of directors

Aug 24

We're Hopeful That Forte Biosciences (NASDAQ:FBRX) Will Use Its Cash Wisely

Aug 17
We're Hopeful That Forte Biosciences (NASDAQ:FBRX) Will Use Its Cash Wisely

Forte Biosciences: Lots Of Clinical Risk Ahead And A Questionable Business Plan

Aug 16

Forte Biosciences large shareholders make demands for company's future

Jul 07

We Think Forte Biosciences (NASDAQ:FBRX) Needs To Drive Business Growth Carefully

Dec 23
We Think Forte Biosciences (NASDAQ:FBRX) Needs To Drive Business Growth Carefully

Forte Biosciences files for $300M mixed shelf offering

May 28

Are Insiders Buying Forte Biosciences, Inc. (NASDAQ:FBRX) Stock?

Mar 13
Are Insiders Buying Forte Biosciences, Inc. (NASDAQ:FBRX) Stock?

Do Institutions Own Forte Biosciences, Inc. (NASDAQ:FBRX) Shares?

Jan 19
Do Institutions Own Forte Biosciences, Inc. (NASDAQ:FBRX) Shares?

Forte Biosciences: FB-401 Potentially Best-In-Class In Atopic Dermatitis

Dec 18

Who Has Been Buying Forte Biosciences, Inc. (NASDAQ:FBRX) Shares?

Nov 25
Who Has Been Buying Forte Biosciences, Inc. (NASDAQ:FBRX) Shares?

Forte Biosciences readies equity offering

Oct 28

Shareholder Returns

FBRXUS BiotechsUS Market
7D7.5%-0.5%0.6%
1Y-28.0%9.6%29.5%

Return vs Industry: FBRX underperformed the US Biotechs industry which returned 10.2% over the past year.

Return vs Market: FBRX underperformed the US Market which returned 29.8% over the past year.

Price Volatility

Is FBRX's price volatile compared to industry and market?
FBRX volatility
FBRX Average Weekly Movement12.3%
Biotechs Industry Average Movement11.5%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: FBRX's share price has been volatile over the past 3 months.

Volatility Over Time: FBRX's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
n/a9Paul A. Wagnerhttps://www.fortebiorx.com

Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.

Forte Biosciences, Inc. Fundamentals Summary

How do Forte Biosciences's earnings and revenue compare to its market cap?
FBRX fundamental statistics
Market capUS$25.84m
Earnings (TTM)-US$31.48m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
FBRX income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$31.48m
Earnings-US$31.48m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.86
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did FBRX perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.